Loading...
BIOV
XCNQ
Market cap2mUSD
May 05, Last price  
H0.07CAD
Name

Biovaxys Technology Corp

Chart & performance

D1W1MN
XCNQ:BIOV chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
56.62%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-4m
L-48.55%
-161,226-230,121-1,174,311-6,457,939-11,727,444-7,687,317-3,954,781
CFO
-2m
L+76.54%
-230,759-1,226,885-5,294,426-1,574,609-1,054,848-1,862,237
H
Trading halted
Reason: Suspended

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.

Key people

Christopher Cherry
Chief Financial Officer · since 2024
Kenneth Kovan
President, Chief Operating Officer · since 2020
Craig Loverock
Director · since 2023
Chief Executive Officer, Director · since 2023
James Tartaglia
Director · since 2025
Independent Director · since 2022
IPO date
Nov 21, 2018
Domiciled in
CA
Incorporated in
CA
Headquarters & legal address
503- 905 West Pender Street
Vancouver, BC V6C1L6
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑102023‑102022‑102021‑102020‑102019‑102018‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT